来源：新浪证券-红岸工作室 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 2月26日，海泰新光跌0.68%，成交额5012.81万元，换手率0.89%，总市值55.75亿元。 今日主力净流入-525.79万，占比0.1%，行业排名96/138，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入-6.67亿，连续3日被主力资金减仓。 异动分析 区间今日近3日近5日近10日近20日主力净流入-525.79万-850.63万-1765.79万-876.82万-4068.79万 医疗器械概念+人民币贬值受益+专精特新 主力持仓 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究 ...

来源：新浪证券-红岸工作室 2月2日，海泰新光跌1.01%，成交额1.17亿元，换手率2.04%，总市值56.22亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 资金分析 今日主力净流入-772.68万，占比0.07%，行业排名100/135，连续2日被主力资金减仓；所属行业主力净 流入-6.62亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-772.68万-837.92万-850.46万-1696.85万-747.98 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscope products [2] Group 1: Company Performance - As of September 30, 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, with a growth of 40.03% [7] - The company's main business revenue composition includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7] - The company has a total market capitalization of 5.472 billion yuan, with a trading volume of 124 million yuan and a turnover rate of 2.29% on January 7 [1] Group 2: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3] - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the Chinese yuan [3] Group 3: Technical Analysis - The average trading cost of the company's shares is 45.92 yuan, with the stock price approaching a resistance level of 46.77 yuan, indicating potential for a price correction if this level is not surpassed [6] - The main capital inflow for the day was 745,700 yuan, with a net inflow of 19.92 million yuan over the past three days, indicating a positive trend in investor interest [5]

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge medical device applications, particularly in high-performance endoscope products, and has a strong vertical integration capability in the industry [2][3]. Group 1: Company Performance - As of September 30, 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, with a growth of 40.03% [7]. - The company's main business revenue composition includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Group 2: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3]. - The company benefits from a significant overseas revenue share of 69.12%, which is positively impacted by the depreciation of the Chinese yuan [3]. Group 3: Stock and Trading Information - On December 22, the company's stock price decreased by 0.54%, with a trading volume of 66.5 million yuan and a turnover rate of 1.29%, resulting in a total market capitalization of 5.126 billion yuan [1]. - The average trading cost of the stock is 46.22 yuan, with the stock price currently near a support level of 41.58 yuan, indicating potential for a rebound if this support holds [6].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price but benefits from its strong position in the medical device sector and the depreciation of the RMB, which enhances its overseas revenue [1][2][3]. Group 1: Company Overview - The company focuses on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments [2]. - Haitai New Light is one of the few companies in China with vertical integration capabilities, covering core components, key equipment, and system integration [2]. - As of September 30, the company reported a revenue of 448 million yuan, a year-on-year increase of 40.47%, and a net profit of 136 million yuan, also up by 40.03% [7]. Group 2: Financial Performance - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the RMB [3]. - The main business revenue composition includes 64.86% from medical endoscopic instruments, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan in the last three years [8]. Group 3: Market Position and Recognition - Haitai New Light has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China [3]. - The company is listed in the medical device sector under the pharmaceutical and biological industry, with various concept segments including medical devices and pension concepts [7].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing growth in its medical device sector, particularly in endoscopic instruments, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Group 1: Company Performance - The company reported a revenue of 448 million yuan for the period from January to September 2025, representing a year-on-year growth of 40.47% [7]. - The net profit attributable to the parent company for the same period was 136 million yuan, showing a year-on-year increase of 40.03% [7]. - The company's main business revenue composition includes 64.86% from medical endoscopic instruments, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. Group 2: Market Position and Recognition - The company has a vertical integration capability in the medical device industry, being one of the few in China that can integrate core components, key equipment, and system integration [2]. - It has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and innovation [3]. Group 3: Financial Metrics and Shareholder Information - As of September 30, 2025, the company had a total market capitalization of 5.381 billion yuan, with a trading volume of 55.8848 million yuan on December 15, 2025 [1]. - The average trading cost of the company's shares is 46.50 yuan, with the current stock price near a support level of 44.54 yuan [6]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price while benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise in the medical device sector [1][2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has a vertical integration capability in the medical device industry, being one of the few in China that can manage core components, key equipment, and system integration [2]. - It has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [3]. Stock Market Activity - On December 11, the company's stock price fell by 2.49%, with a trading volume of 43.66 million yuan and a turnover rate of 0.82%, leading to a total market capitalization of 5.247 billion yuan [1]. - The stock has seen a net outflow of 12,500 yuan from major investors today, with a total net outflow of 503 million yuan from the industry over the past three days [4][5].

出海已成为企业突破增长天花板、构建全球竞争力的必由之路，也成为当下资本市场与产业界共同聚焦的核心热点。 那么，中国企业出海的背后驱动因素有哪些，面临怎样的全球化机遇，在深化全球化布局的过程中面临哪些挑战，又该如何化解风险？ 12月2日，在第一财经联合安永（中国）、矽亚资产管理等专业机构举办的"未来20·2025A股上市公司成长力年会"上，安永大中华区经济咨询服务合伙人余 泠担任主持人，与华明装备（002270.SZ）董事长肖毅，宝光股份（600379.SH）副董事长原瑞涛，海泰新光（688677.SH）副总经理、董秘、财务总监汪方 华，花旗银行（中国）有限公司副行长、商业银行部负责人、董事总经理林海四位嘉宾就上述热点问题展开了深度探讨。 "服务、配件本地化后，就把我们服务和生态根植到客户的心里了，这样才会有生命力。"肖毅说，"走出去"后，要"走进去"，并扎根下去，只有这样才能在 当地真正形成生态圈。 林海也观察到，中国企业布局全球化，已明显从跑马圈地进入到如何扎根共生的阶段，不再是简单把货卖出去、把厂开出去，而是要在不同的土壤里，做品 牌、建立信任和构建生态。 多重因素驱动企业出海 企业出海的核心驱动因素因主 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge medical device applications, particularly in high-performance endoscope products, and has a strong vertical integration capability in the industry [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company is as follows: medical endoscope devices 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3]. - As of the latest report, 69.12% of the company's revenue comes from overseas markets, benefiting from the depreciation of the Chinese yuan [3]. Stock Performance - On December 4, the stock price of Haitai New Light decreased by 0.04%, with a trading volume of 27.27 million yuan and a turnover rate of 0.50%. The total market capitalization is 5.45 billion yuan [1]. - The average trading cost of the stock is 46.62 yuan, with recent buying activity observed, although the buying pressure is not strong. The stock is currently trading between a resistance level of 46.80 yuan and a support level of 42.48 yuan [6].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments [2] Group 1: Company Overview - The company was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products [7] - The revenue composition of the company is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7] - As of September 30, the company had 5,188 shareholders, a decrease of 1.84% from the previous period, with an average of 23,106 circulating shares per shareholder, an increase of 1.87% [7] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a year-on-year increase of 40.03% [7] - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8] Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3] - The company benefits from a high overseas revenue proportion of 69.12%, aided by the depreciation of the Chinese yuan [3] Group 4: Technical Analysis - The average trading cost of the company's shares is 46.62 yuan, with recent chip reduction slowing down. The current stock price is near a resistance level of 45.45 yuan, indicating potential for a price correction if this level is not surpassed [6]